31
Participants
Start Date
October 31, 2007
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
Dasatinib
An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
Duke University Medical Center, Durham
Presbyterian Health Care, Charlotte
Palm Beach Cancer Center Institute, West Palm Beach
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Duke University
OTHER